FDA review panel: Medtronic Symplicity Spyral renal denervation (RDN) risks outweigh benefits
The FDA review panel voted against recommending approval of Medtronic's renal denervation therapy for hypertension, citing concerns about its efficacy and the lack of evidence supporting its proposed indications.